Upstate Active Clinical Trials

Study Title:

EA5221- A Randomized Phase III Trial of Chemo-Immunotherapy vs Immunotherapy Alone for the Vulnerable older adult with Advanced Non-Small Cell Lung Cancer: The ACHIEVE Study

What is the purpose of the study? (in Layman's terms, please describe the study)

To evaluate whether there is an improvement in overall survival (OS) with chemotherapy combined with pembrolizumab compared to single agent pembrolizumab in this vulnerable older adult patient population.

Upstate Institutional Review Board (IRB) Number:

2179184

Study/Protocol ID:

EA5221-The ACHIEVE Study

Study Phase:

Phase IIII

Patient Age Group:

Adults

Principal Investigator:

Stephen L Graziano, MD

What is involved if I participate?

• How long is the study?
  For this protocol, all patients, including those who discontinue protocol therapy early, will be followed for response until progression, even if non-protocol therapy is initiated, and for survival for 5 years from the date of randomization. All patients must also be followed through completion of all protocol therapy.
• Is transportation provided or reimbursed?
  No
• Is parking provided or reimbursed?
  No
• What tests and procedures are involved?
  N/A

Where will the study take place?

Upstate-All procedures
Oswego-All procedures
Verona-All procedures
Community- All procedures

Other Information:

n/a

ClinicalTrials.Gov ID:

NCT06096844

For more information about this trial go to ClinicalTrials.Gov

Who can I contact for more information?

Name: Sarah A Knutson
Phone: 315-464-8237
Email: [email protected]

Return to Previous Page || Search Again